TargetBeta-lactamase(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of Escherichia coli CTX-M-15More data for this Ligand-Target Pair
TargetBeta-lactamase(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of Escherichia coli CTX-M-15More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 33.4nMAssay Description:Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase FtsI(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 68.9nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPenicillin-binding protein 3(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 93.5nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPenicillin-binding protein 2(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 180nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase FtsI(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 182nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase FtsI(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 187nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPutative penicillin-binding protein 2B(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 187nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 1More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase FtsI(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 208nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 334nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase FtsI(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 334nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 360nMAssay Description:Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 374nMAssay Description:Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPutative penicillin-binding protein 2B(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 901nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 1More data for this Ligand-Target Pair
TargetPenicillin-binding protein 1B(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 935nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1bMore data for this Ligand-Target Pair
TargetPenicillin-binding protein 2(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 935nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.24E+3nMAssay Description:Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPenicillin-binding protein 1B(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.67E+3nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1bMore data for this Ligand-Target Pair
TargetPeptidase(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.68E+3nMAssay Description:Inhibition of bocillin FL binding to methicillin-resistant Staphylococcus aureus OC 3726 penicillin-binding protein 2aMore data for this Ligand-Target Pair
TargetPenicillin-binding protein 3(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 3More data for this Ligand-Target Pair
TargetPenicillin-binding protein 4(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.87E+3nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 4More data for this Ligand-Target Pair
TargetPenicillin-binding protein 1B(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.16E+3nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1bMore data for this Ligand-Target Pair
TargetPenicillin-binding protein 1B(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.59E+3nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1bMore data for this Ligand-Target Pair
Affinity DataIC50: 5.10E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 5.10E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 5.61E+3nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 7.31E+3nMAssay Description:Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2More data for this Ligand-Target Pair
Affinity DataIC50: 7.50E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 7.50E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 8.10E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
Affinity DataIC50: 8.10E+3nMAssay Description:Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by...More data for this Ligand-Target Pair
TargetPenicillin-binding protein 1B(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 9.14E+3nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1bMore data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.66E+4nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPenicillin-binding protein 4(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.80E+4nMAssay Description:Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 4More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Escherichia coli)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.83E+4nMAssay Description:Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 3.67E+4nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidoglycan D,D-transpeptidase MrdA(Pseudomonas aeruginosa)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >5.85E+4nMAssay Description:Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2More data for this Ligand-Target Pair
TargetPeptidase(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >9.01E+4nMAssay Description:Inhibition of bocillin FL binding to methicillin-resistant Staphylococcus aureus OC 3726 penicillin-binding protein 2aMore data for this Ligand-Target Pair
TargetPeptidase(Staphylococcus aureus)
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >9.14E+4nMAssay Description:Inhibition of bocillin FL binding to methicillin-resistant Staphylococcus aureus OC 3726 penicillin-binding protein 2aMore data for this Ligand-Target Pair
Affinity DataKd: 1.43E+4nMAssay Description:Binding affinity to SARS-CoV-2 3CL protease at 1.875 to 50 uM by SPR assayMore data for this Ligand-Target Pair
Affinity DataKd: 1.43E+4nMAssay Description:Binding affinity to SARS-CoV-2 3CL protease at 1.875 to 50 uM by SPR assayMore data for this Ligand-Target Pair
Affinity DataKd: 1.66E+4nMAssay Description:Binding affinity to SARS-CoV-2 3CL protease at 1.875 to 50 uM by SPR assayMore data for this Ligand-Target Pair
Affinity DataKd: 1.66E+4nMAssay Description:Binding affinity to SARS-CoV-2 3CL protease at 1.875 to 50 uM by SPR assayMore data for this Ligand-Target Pair
Affinity DataKd: 6.47E+4nMAssay Description:Binding affinity to SARS-CoV-2 Spike glycoprotein receptor-binding domain at 1.875 to 50 uM in presence of wallichins C by SPR assayMore data for this Ligand-Target Pair
Affinity DataKd: 9.17E+4nMAssay Description:Binding affinity to SARS-CoV-2 Spike glycoprotein receptor-binding domain at 1.875 to 50 uM by SPR assayMore data for this Ligand-Target Pair